Author

J.-P. Villemin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:differential expression· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Casanova· 1 shared A. Gey· 1 shared A. Maraver· 1 shared A. Oldfield· 1 shared A. Pradines· 1 shared C. Delahaye· 1 shared C. Lorenzi· 1 shared C. Tardy· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Casanova

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Differential predictive value of resident memory CD8+T cell subpopulations in non-small-cell lung cancer patients treated by immunotherapy

L. Paolini, T. Tran, S. Corgnac, J.-P. VILLEMIN, M. Wislez, J. Arrondeau, L. Johannes, J. Ulmer, L.-V. Vieillard, J. Pineau, A. Gey, V. Quiniou, P. Barennes, H. P. Pham, n. Gruel, , E. TARTOUR

The paper identifies two TRM subpopulations in NSCLC patients and shows that only DP TRM predicts response to PD-1 blockade immunotherapy.

bioRxiv · Mar 7, 2024Immunology

Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR-mutant NSCLC

S. Figarol, C. Delahaye, R. Gence, R. Asslan, S. Pagano, C. Tardy, J. Colinge, J.-P. Villemin, A. Maraver, I. Ferrer, L. Paz-Ares, I. Lajoie-Mazenc, E. Clermont, A. Casanova, A. Pradines, , G. Favre

This study identifies early escapers as a rare cell population resistant to EGFR-TKi and shows that tipifarnib overcomes this resistance by targeting Rho/ROCK pathway and preventing relapse.

bioRxiv · Apr 1, 2022 · PreprintCancer Biology

A cell-to-patient machine learning transfer approach uncovers novel basal-like breast cancer prognostic markers amongst alternative splice variants

J.-P. Villemin, C. Lorenzi, A. Oldfield, M.-S. Cabrillac, W. J. Ritchie, R. F. Luco

This paper uses a machine learning approach to transfer knowledge from breast cancer cell lines to patient data, identifying a splicing signature that subclasses basal-like breast cancers and predicts poor prognosis.

bioRxiv · Nov 12, 2020Cancer Biology